Back to Newsroom

ECOG-ACRIN Opens Phase III Trial of Syndax’s Entinostat in Advanced Breast Cancer

Entinostat is being investigated in patients with advanced hormone receptor-positive breast cancer by the ECOG-ACRIN Cancer Research Group in its latest trial, E2112.

Philadelphia, PA, and Waltham, MA, March 20, 2014 –The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and Syndax Pharmaceuticals, Inc., announced today that patient recruitment has begun for E2112, a randomized phase III clinical trial of Syndax’s entinostat in treatment of patients with advanced breast cancer. The trial will evaluate whether the addition of entinostat to endocrine therapy (exemestane) improves progression-free survival and/or overall survival in men and postmenopausal women with hormone receptor-positive, human epidermal growth factor 2-negative advanced breast cancer who have previously progressed on a nonsteroidal aromatase inhibitor.